Clik here to view.
In conversation with Dr. Isaac Ciechanover
Dr. Isaac Ciechanover As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to...
View ArticleClik here to view.
In conversation with Heather Morehouse Ettinger
Heather Morehouse Ettinger As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting,...
View ArticleClik here to view.
Soricimed completes Phase 1 cancer trial with SOR-C13
Closely-held Soricimed Biopharma has reached its target enrollment and treatment duration in a Phase 1 trial to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who...
View ArticleClik here to view.
Roth starts Prima BioMed at buy
Roth Capital Partners has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and price target of $6. The stock closed at $1.11 on Wednesday. “We believe Prima is in a leading position...
View ArticleClik here to view.
Stellar Biotechnologies harvests mollusks for KLH protein
A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Frank Oakes Stellar Biotechnologies...
View ArticleClik here to view.
Canaccord starts Vermillion at buy
Canaccord Genuity has launched coverage of Vermillion (NASDAQ:VRML) with a “buy” rating and $4 price target. The stock closed at $1.89 on Monday. “We believe Vermillion is on track to expand into a...
View ArticleClik here to view.
In conversation with Paul Gunn
Paul Gunn As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005...
View ArticleClik here to view.
Juniper Pharma’s lidocaine vaginal gel data due in Q3
Frank Condella, President and CEO Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel,...
View ArticleClik here to view.
Soricimed announces members of CAB
Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB). The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer...
View ArticleClik here to view.
HCW analyst assumes coverage of Celsion
H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $3 price target. The stock closed at $1.30 on Monday. Celsion has developed two...
View Article
